Moody Lynn & Lieberson LLC Acquires 2,274 Shares of Stryker Corporation $SYK

Moody Lynn & Lieberson LLC boosted its stake in Stryker Corporation (NYSE:SYK) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 90,072 shares of the medical technology company’s stock after acquiring an additional 2,274 shares during the period. Stryker accounts for about 1.8% of Moody Lynn & Lieberson LLC’s holdings, making the stock its 18th biggest position. Moody Lynn & Lieberson LLC’s holdings in Stryker were worth $33,297,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Stryker in the 2nd quarter worth approximately $26,000. Clayton Financial Group LLC purchased a new stake in Stryker in the third quarter worth $26,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Stryker in the second quarter valued at $28,000. Sachetta LLC lifted its position in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the last quarter. Finally, Kilter Group LLC bought a new position in shares of Stryker during the 2nd quarter worth $29,000. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

Shares of NYSE:SYK opened at $354.20 on Wednesday. The company’s fifty day moving average price is $362.68 and its 200-day moving average price is $376.10. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The firm has a market capitalization of $135.45 billion, a price-to-earnings ratio of 46.54, a PEG ratio of 2.50 and a beta of 0.89. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Friday, October 31st. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the prior year, the firm earned $2.87 earnings per share. Stryker’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s payout ratio is 44.15%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Citigroup lowered their price objective on Stryker from $455.00 to $420.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. UBS Group set a $408.00 target price on shares of Stryker in a research note on Monday, October 13th. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Needham & Company LLC restated a “buy” rating and set a $448.00 price target on shares of Stryker in a research note on Friday, November 14th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 price objective on shares of Stryker in a research note on Friday, November 14th. Thirteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $431.84.

Insider Activity at Stryker

In other Stryker news, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares in the company, valued at approximately $2,449,200.72. This represents a 2.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 522,118 shares of company stock worth $185,381,932 over the last quarter. Corporate insiders own 5.20% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.